Industry News

Crack GPAT — Prepare for GPAT Online 
  • Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
    4 December 2025

    Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

    Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.
  • 4 December 2025
    Celltrion announces USFDA approval of 300mg strength of OMLYCLO® (omalizumab-igec)
    Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg/2mL solution in a single-dose prefilled syringe for subcutaneous injection. In the U.S., OMLYCLO will be marketed and distributed exclusively by Celltrion USA, Inc.
  • 3 December 2025
    Sun Pharma introduces its global innovative drug, Ilumya® in India
    Sun Pharmaceutical Industries Ltd. announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.
  • 1 December 2025
    Sandoz launches denosumab biosimilars in Europe
    Sandoz the global leader in affordable medicines, today announced the European launch of Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg).
  • 1 December 2025
    Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
    Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.
  • 22 November 2025
    BE’s New 14-Valent Pneumococcal Vaccine Secures WHO Pre-Qualification

    Biological E. Limited (BE), one of India’s leading vaccine and pharmaceutical manufacturers, has announced a major milestone with the World Health Organisation (WHO) granting Pre-qualification (PQ) status to its 14-valent Pneumococcal Conjugate Vaccine, PNEUBEVAX 14 (BE-PCV-14). This achievement marks the company’s 11th vaccine to enter the WHO PQ portfolio, strengthening its presence among global immunisation suppliers.

  • 18 November 2025
    AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India
    AstraZeneca Pharma India Limited a leading science-led biopharmaceutical company and Sun Pharmaceutical Industries Limited today announced a second brand partnership for Sodium Zirconium Cyclosilicate in India.
  • 17 November 2025
    Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
    Sandoz, the global leader in affordable medicines, today announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by Polpharma Biologics, TYRUKO® is the first and only US Food and Drug Administration (FDA) approved natalizumab biosimilar for the treatment of relapsing forms of multiple sclerosis (MS).
  • 17 November 2025
    Lupin’s Nagpur Unit-1 Clears U.S. FDA Pre-Approval Inspection with No Observations
    Global pharmaceutical company Lupin Limited announced today that the United States Food and Drug Administration (U.S. FDA) has successfully completed a product-specific pre-approval inspection at its Unit-1 oral solid dosage facility in Nagpur.
  • 17 November 2025
    Merck to Acquire Cidara Therapeutics, Inc

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for 221.50 USD per share in cash, for a total transaction value of approximately 9.2 billion USD.

Subscribe to Industry News

FOR LATEST UPDATES, CLICK TO JOIN AT WHATS APP >>

Add PharmaTutor as preferred source on Google >>

RECOMMENDED POSTS

Recent content